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Background: The Human Papillomavirus (HPV) is generally recognized to be the direct cause of cervical cancer.
The development of effective anti-HPV vaccines, included in the portfolio of recommended vaccinations for any
given community, led to the consolidation in many countries of immunization programs to prevent HPV-related
cervical cancers. In recent years, increasing evidence in epidemiology and molecular biology have supported the
oncogenic role of HPV in the development of other neoplasm including condylomas and penile, anal, vulvar,
vaginal, and oro-pharyngeal cancers. Men play a key role in the paradigm of HPV infection: both as patients and as
part of the mechanisms of transmission. Data show they are affected almost as often as women. Moreover, no
screening procedures for HPV-related disease prevention are applied in men, who fail to undergo routine medical
testing by any medical specialist at all. They also do not benefit from government prevention strategies.
Discussion: A panel of experts convened to focus on scientific, medical, and economic studies, and on the
achievements from health organizations’ intervention programs on the matter. One of the goals was to discuss on
the critical issues emerging from the ongoing global implementation of HPV vaccination. A second goal was to
identify contributions which could overcome the barriers that impede or delay effective vaccination programs
whose purpose is to eradicate the HPV infection both in women and men.
Summary: The reviewed studies on the natural history of HPV infection and related diseases in women and men,
the increasing experience of HPV vaccination in women, the analysis of clinical effectiveness vs economic efficacy
of HPV vaccination, are even more supportive of the economic sustainability of vaccination programs both in
women and men. Those achievements address increasing and needed attention to the issue of social equity in
healthcare for both genders.
Keywords: HPV infection, Condylomas, Cervical cancer, Genital cancer, Oro-pharyngeal cancer, Anti-HPV vaccines,
Universal vaccination, Vaccination programs, Incremental cost-effectiveness ratioBackground
Human Papillomavirus (HPV) infection is the most
widely spread sexually transmitted infection in some
areas of the world, with up to 70% of the population
expected to become infected at some point of their life-
time [1,2]. The majority of these infections are subclin-
ical, unrecognized, and benign [3,4]. Since HPV was
discovered to be the direct cause of cervical cancer [5,6],* Correspondence: andrea.peracino@lorenzinifoundation.org
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distribution, and reproduction in any mediumscientific data paired to the development of effective
anti-HPV vaccines, accepted by health organizations,
and included in the portfolio of recommended vaccina-
tions for the community, have led to the consolidation
in many countries of immunization programs to prevent
HPV-related cervical cancers. Knowledge and experience
accrued thus far, support and better address prevention
programs in utilizing HPV vaccination for the benefit of
the community. HPV infection, earlier correlated only to
cervical carcinoma, today is acknowledged to be primar-
ily responsible for cancerous and precancerous lesions of
the genital area in both males and females and, in atral Ltd. This is an Open Access article distributed under the terms of the
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head and neck cancers [7,8]. Although HPV infections
are known to be mainly a sexually transmitted disease,
recent studies in non-sexually abused children infected
with HPV suggest different forms of transmission [9,10].
Reports on the non-sexual transmission of anogenital
warts, e.g. by prenatal mode, show the importance of
maternal gynecologic history [11], and can help to
understand better suspected sexual abuse in children
[12]. Hand-genital transmission in adults should also be
considered as a non-sexual means of transmission of
HPV [13,14] although it has yet to be confirmed [15].
Until today, HPV prevention strategies through vac-
cination have targeted women mainly against cervical
cancer. HPV vaccination, as efficacious means to reduce
the development of cervical cancer in women in primary
intervention strategies, has already been shown to be
highly effective in reducing HPV-related lesions, such as
genital warts as well as CIN 2/3 [16,17]. The significant
declines in the proportion of young women found to
have genital warts and the absence of genital warts in
vaccinated women in 2011 suggests that the human pap-
illomavirus vaccine has a high efficacy outside of the trial
setting. Vaccination is undoubtedly a primary prevention
tool; furthermore the expected eradication of the most
prevalent HPV types will decrease the need of intense
screening (secondary prevention) and cervical excisions
for high grade disease (tertiary prevention). Now in-
creasing evidence demonstrates how important the
burden of HPV-correlated diseases also is in men.
Epidemiological data show that in Europe and the USA,
the burden of HPV-related head and neck cancers is
carried mainly by men (4 times more than women),
which shows that males are more than mere vectors
[18,19]. Between 2006 and 2007 many countries have
implemented HPV vaccination programs only for girls
around 12 years of age. In the beginning the two avail-
able and approved vaccines were intended to target fe-
males only. After the approval of the quadrivalent
vaccine (HPV4) indications for men, the USA, Canada,
and Australia now recommend routine vaccination for
both men and women. Men however are not yet in-
cluded in nationally funded routine HPV vaccination
programs in Europe (except Austria) and in many other
countries.
Data on disease burden, vaccine efficacy, vaccine
safety, cost-effectiveness, and social and ethical factors
need to be taken into consideration when authorities de-
cide to add men to European HPV vaccination pro-
grams. This paper summarizes the topics debated by a
panel of experts convened to focus on scientific, medical,
and economic studies, and on achievements from health
organizations’ intervention programs on the matter. The
goal is to better develop a knowledge platform to beused to further support and promote eradication of HPV
infections in both women and men. The discussion was
structured to identify contributions which could over-
come common barriers that impede or delay effective
vaccination programs whose purpose is to eradicate the
HPV infection in both women and men.
Discussion
Natural history of HPV infection in women and men
The increased understanding of the natural history of
HPV infection recently supported one of the main
breakthroughs of medical science. HPVs are double-
stranded DNA viruses that replicate within stratified
squamous epithelia that need micro-abrasions or areas
of transitional epithelium, such as in the cervix, anus,
and tonsils, to be able to infect epithelial cells [20]. After
infection, the virus makes use of the cells’ normal DNA
replication machinery to produce further viral genetic
fragments at the supra-basal layer of the epithelium
[20,21]. Like all papillomaviruses, HPVs establish pro-
ductive infections only in keratinocytes of the skin or
mucous membranes. While the majority of the known
HPV infections cause no symptoms in most people and
are usually spontaneously cleared by the host, some
types can cause warts while others may lead – in a few
cases – to cancers of the cervix, vulva, vagina, penis,
anus, and oro-pharynx. More than 130 genotypes of
HPV have been described; types are divided into high
risk and low risk according to their ability to produce
benign or malignant lesions over time. The main high
risk HPV types, classified as carcinogenic to humans by
the International Agency for Research and Cancer
(IARC) since 1995 [22], are HPV types 16 and 18, which
are responsible of about 70% [2,23] of cervical cancers
worldwide and most HPV-related pre-cancerous lesions
in other anatomical regions whether genital or not
[24,25]. Among the low risk types, HPV types 6 and 11
account for approximately 90% of genital warts. Seventy
percent of infections are usually cleared after one year
and 90% in two years [20,26]. However, when the in-
fection caused by high risk (HR) genotypes of HPV, per-
sists – in 5% to 10% of infected women – there is a high
probability of developing precancerous lesions of the
cervix, which can progress to invasive cervical cancer.
This process usually takes 10-15 years, providing many
opportunities for prevention, detection, and treatment of
the pre-cancerous lesion involved [21]. Several models
show that what one may consider today as remission of
infection might not be remission at all [20]. As already
mentioned, increasing evidence in epidemiology and
molecular biology have supported the oncogenic role of
HPV in the development of other genital cancers includ-
ing penile, anal, vulvar, and vaginal cancers [27,28] and
some oro-pharyngeal cancers [8,29-31] that share
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vical areas [32]. Several risk factors seem to affect HPV
infection, from the number of sexual partners [33,34]
and oral contraceptive use [35] to smoking and alcohol:
the latter ones particularly related to head and neck can-
cers [36]. Other risk factors have been studied including
condom use [37] and circumcision [38,39]. In women,
evidence suggests two HPV incidence high peak points
at < 25 and around 45 years of age [40]. On the other
hand, in men, HPV prevalence and incidence seem to be
constantly high at all ages [41,42]. The most common le-
sions in both sexes are anogenital warts (AGW), mainly
attributable to HPV types 6 and 11 (> 90%). Of these
cases, 20-50% involve co-infection with other high risk
HPV types [27,43]. In fact, studies have demonstrated
that both in females and males, AGW patients have a
higher risk of developing HPV-related cancers [44].
These results seem to contradict statements from the
American Centers for Disease Control (CDC) (2010)
which indicate that AGW, except in very rare and un-
usual cases, will not turn in cancer. The types of HPV
that cause AGW are different from the types that can
cause anogenital cancer; however, subjects with low risk
(LR) HPV types should be considered at higher risk of
having cancer by HPV 16 in the future. Knowledge of
natural history and epidemiology of HPV in men is con-
stantly increasing although it still remains less extensive
than in women. Cancers related to HPV diagnosed every
year in males have been shown to be approximately half
the number of HPV-related cancer cases in women. This
proportion of 1:2 (not 1:100 or 1:1000) is significant,
without taking into account other less severe HPV-
related diseases that have a higher incidence and
life-long-prevalence in men than in women. HPV-16 and
-18 are found to account for 90% of all HPV-related can-
cers in men [45]. The most recent studies in Europe
show that 17,403 cancer cases in men are expected to be
HPV-related, 15,497 of which are attributable exclusively
to HPV types 16 and 18 vs 32,562 which are expected to
be related to these two types in women [19]. In addition
it has also been estimated that there will be around
650,000 new cases each year of genital warts, more than
50% of which are expected in men. Similar data are con-
firmed by the most recent WHO (World Health
Organization) statistical report on HPV in Europe [46].
A recent study conducted by Baio et al. [47] showed that
the burden of HPV-related disease in Italy behaves simi-
larly to that in Europe, with males playing an important
role. The latest CDC data [18] on burden of disease in
males display the same trend as Hartwig et al. [19] with
almost half the number of cases of HPV-related cancer
as women determined in Europe. Overall an average of
33,369 HPV-associated cancers (10,8 per 100.000 popu-
lation), were diagnosed annually: 21,290 among women(13,2 per 100.000 population) and 12,080 among men
(8,1 per 100.000 population). Cervical cancer was the
most common, and oropharyngeal cancer ranked as the
second most common. HPV-related head and neck can-
cer incidence in the USA is already higher in men, and
should no action be taken, is expected to exceed that of
cervical cancer by 2020 [18]. Anal cancer is a rare can-
cer; however, it has a very high incidence in men who
have sex with men (MSM), where the incidence is esti-
mated to be equivalent to that in women with cervical
cancer, ranging from 32.8% to 93.5% [48-50], with an es-
timated risk of anal cancer 30 times [51,52] and genital
warts around 10 times [53] higher than in heterosexual
men. However not all cancers termed “HPV-associated”
reflect actual infections and the numbers judged to be
HPV-attributable are only estimates. The same MMWR
editorial concludes: “Population-based screening for
non-cervical HPV-associated cancers is not recomm-
ended” [18].
Critical issues in HPV vaccination
Immunogenicity, safety, and clinical significance repre-
sent the critical issues on which to base the prospective
of the eradicating HPV-related diseases through a global
implementation of multivalent HPV vaccination.
Two vaccines are currently available to prevent HPV
infection. The bivalent vaccine (HPV2) targets HPV
types 16 and 18 [54], while the quadrivalent vaccine
(HPV4) targets HPV types 6, 11, 16, and 18 [55]. Both
vaccines have demonstrated high efficacy in the preven-
tion of cervical precancerous lesions, long-term im-
munogenicity and efficacy, and to be safe and well
tolerated in females up to 25 years of age. HPV4 vaccine
has also demonstrated, together with the protection
against cervical cancer, high efficacy against genital warts
from HPV types 6 and 11, against vaginal and vulvar
precancerous lesions, re-infection, persistent infection,
and anal precancerous lesions (AIN 1,2,3 studied in an
MSM population) [56-58]. HPV4 vaccine is also indi-
cated for the use in females up to 45 years of age and in
males up to 26 years of age by the European Medicines
Agency (EMA) in Europe. Both vaccines are currently
employed in girls in many national vaccination cam-
paigns and have proven to be safe, well tolerated, and
highly efficacious in preventing persistent infections and
cervical diseases associated with specific HPV types
among females [59]. Studies about long-term duration of
efficacy are still ongoing for both vaccines, and are
around 9 years without breakthroughs. Time is needed
to clarify the issues of long-term duration of efficacy and
immunogenicity and whether a vaccine boost will be re-
quired or not [60-62]. Through mathematical modeling
Fraser et al. evaluated the long-term anti-HPV-16
responses following administration of a three-dose
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Using a conventional power law model a median dur-
ation of detectable antibody (> 5.9 mMU/mL) of 32 years
has been estimated; whereas the modified power law
model predicted a long-term plateau of antibody dur-
ation with a nearly life-long persistence above the level
of detection (> 5.9 mMU/mL) [63].
As mentioned before, the HPV burden of disease has
been demonstrated to be quite high in men as well. Re-
cent randomized studies have been conducted in order
to assess efficacy, immunogenicity, and safety of the
quadrivalent vaccine in men and included 4,065 young
male subjects aged between 16 and 26 years of age, 602
of which self-declared to have sex with other men. Vac-
cine efficacy against external genital lesions (EGL) was
found to be 90.4% and 89.4% against genital warts [56]
(Table 1). The study by Giuliano and colleagues showed
efficacy of 92.4% against genital warts in the heterosex-
ual male population and 79% in the MSM population;
for persistent infection the vaccine proved to have an ef-
ficacy of 50.4% for heterosexual males and 43.6% for
MSM [56]. The same trial conducted to evaluate any
grade of anal intraepithelial neoplasia (AIN) in MSM
showed an overall efficacy on the per protocol popula-
tion of 77.5% [57]. An exclusively post-hoc efficacy ana-
lysis for vaccine types of 92% was reported [58]. The
studies [56-58] on male vaccine efficacy are summarized
in Table 2. Efficacy of vaccine was bridged to males 10-
15 years old with an immune-bridging study that dem-
onstrated non-inferiority immune response compared to
females aged 16 to 23 [64]. These studies are the basis
for vaccine approval for males and male vaccination rec-
ommendations by EMA and FDA (Food and Drug
Administration).
HPV vaccines have been demonstrated to be safe over
the last 10 years. Most available data is on women, as
they were the primary target of vaccination. Data on im-
munogenicity and safety are available however also for
men and demonstrated that both HPV2 and HPV4 have
immunogenicity and favorable safety profile similar to
the studies conducted in women [65]. Both HPV
vaccines are closely monitored worldwide and post-Table 1 HPV4 vaccine efficacy study against external genital
of age (n = 4065) [56]
Endpoint HPV4 (n = 1397)
N° cases
All external genital lesions 3
Condyloma 3
Penile/perianal/perineal intraepithelial neoplasia 0
Persistent infection (all HPV types) 15
DNA detection 136licensure studies have shown good safety profiles
[66,67].
The clinical significance of HPV vaccination has been
extensively studied in specific communities.
In the province of Victoria (Australia) an ecological
study compared the incidence of high-grade pre-
neoplastic and cancers (CIN 2+) lesions detected in
women < 18 years of age examined before and after the
start of an HPV4 vaccination program in young girls
aged 12-to-13 years old [16]. A progressive decrease in
the incidence of high-grade lesions by 0.38% has been
observed in the girls younger than 18 years in a region
where the vaccination coverage was between 71% and
79%. Another Australian ecological follow-up study [17]
showed that after 5 years from the beginning of the vac-
cination program, genital incidence of new cases of geni-
tal wart dropped by 93%. Some herd immunity was also
observed in males of the same age group, although inci-
dence remained high in the MSM population [17]. Two
other studies conducted in New Zealand [68] and
California (USA) [69] – where the coverage of vaccin-
ation programs of the target population was rarely over
50% – showed around 60% and 30% reduction of genital
warts, respectively. Evidence seems to support vaccine
efficacy and reduction of disease with some herd im-
munity effect in heterosexual males but not in MSM. A
rapid and marked reduction in the incidence of genital
warts occurred among vaccinated women, and this re-
duction could mean some benefit being conferred to
heterosexual men [70], but not to MSM. A rapid decline
in presentation of genital warts was observed after im-
plementation of a national program with HPV4 vaccine
[70]. Given the success of Australia’s catch-up program,
it will not be long before we know if the basic reproduct-
ive number for genital warts holds the prospect of elim-
ination. However, if genital warts stabilize at a lower, but
not very low, rate we will know that elimination will not
be possible without vaccination of males [71].
International policies and recommendations
Vaccination and vaccines are undoubtedly one of the
most innovative procedures with the greatest impact onlesions and persistent HPV infection in men 16-26 years
Placebo (n = 1408) Efficacy (%) 95% CI
N° cases
31 90.4 (all HPV types) 62.2-97.9
28 89.4 65.5-97.9
3 100 0-100
101 85.6 73.4-92.9
241 44.7 31.5-55.6
Table 2 Summary of HPV4 vaccine efficacy studies in men [56-58]
Giuliano Palefsky Goldstone
Population Per-protocol Per-protocol Per-protocol*
(16-26 years) (16-26 years) (16-26 years)
External genital lesions 90.4%
(95% CI: 69.2-98.1)
Anal intraepithelial neoplasia 77.5% 91.7%
(95% CI: 39.6-93.3) (95% CI: 44.6-99.8)
Condylomata acuminata 89.4%
(95% CI: 65.5-97.9)
* Post-hoc analysis.
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policies achieve almost complete eradication of diseases
once thought to be lethal.
In Europe, recommendations for HPV vaccination in
females have been introduced in nearly all Western
European countries with some of them also offering na-
tional or regional funding programs. It was first intro-
duced in 2007 in Belgium, France, Germany, and Italy.
In 2008 other countries also recommended vaccination,
such as Greece, Luxembourg, the Netherlands, Romania,
Spain, Switzerland, and the UK. Other European coun-
tries followed (Denmark, Norway, Portugal, San Marino,
and Macedonia). The latest to start were Sweden and
Ireland in 2010. As of today the vaccination advisory
boards in 21 of the 29 countries of the EU have
recommended and have in place active HPV vaccination
programs [72]. In other countries (Czech Republic,
Slovenia, Latvia, and Iceland), HPV vaccination has been
recommended but has not been actually integrated in
the national immunization programs. Some countries
not only initiated their programs with the primary co-
hort of females but also have implemented different vac-
cination cohorts or catch-up programs. In Italy, the
Basilicata region started in 2007/08 with a 4-cohort
strategy covering females up to 25 years of age and as-
suring coverage of all females up to 21 years of age in
2012. This has resulted in average coverage rates in the
primary cohort of around 80% and represents an excel-
lent paradigm. Data collected by the VENICE2 Group in
2010 [72] registered a high heterogeneity in the strat-
egies for implementation of the HPV vaccination in
European countries. Recommendations for the vaccin-
ation starting age range from 10 to 18 and the catch-up
rounds from age 12 to 24. So far the targets are girls/
women in all European countries except Austria, which
already targets but does not fund vaccination in males as
well as females.
Today, in fact, the HPV4 vaccine is also indicated by
the main health organizations (e.g. FDA, EMA) for
males up to 26 years of age.The US initially recommended routine vaccination of
females between 11 and 12 years of age, with catch-up
programs up to 26 years of age. Although the private
American health system is not comparable to most pub-
lic European health systems, the vaccine was offered for
free both to the health-insured population and to the
uninsured through Medicaid and the Vaccine for Chil-
dren (VFC) program that offered the vaccine for free to
girls up to 18 years of age. Even so, the US found several
obstacles to reach high rates of vaccine coverage effect-
ively in all regions, with an average coverage of only
around 20% [73]. In 2011, the CDC Advisory Committee
on Immunization Practices (ACIP) took into account
new efficacy data on the vaccines, the low coverage
rates, and the updated burden of disease knowledge and
decided to recommend routine vaccination for both
men and women, a gender-neutral vaccination offered
free of charge, both to insured and uninsured people up
to their 18th birthday [74]. To support this decision, the
American Academy of Pediatrics [75] recommended the
vaccination of males as well as females. This new strat-
egy is expected to further reduce the burden of the dis-
ease. In 2007 Canada and Australia which have national
health systems decided to vaccinate women at the start
of the program through school-based programs. Doing
so, vaccine coverage reached higher coverage rates, ran-
ging from 63.7% to 79.6% in Australia and from 50% to
85% in Canada [76-78]. The latest epidemiological stud-
ies in Australia show an almost complete disappearance
of genital warts diagnosis: with a coverage of 83% of
women < 21 years who received the first dose of the vac-
cine, the diagnosis of genital warts declined by 93% by
the fifth year of the national quadrivalent HPV vaccin-
ation program [17]. In late 2011 and early 2012, both
PBAC (Pharmaceutical Benefits Advisory Committee)
and the NACI (National Advisory Committee on
Immunization) [78] vaccine bodies in Australia and
Canada have decided to recommend routine HPV vacci-
nations for males and females; the program started in
Australia in January 2013.
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with the HPV4 vaccine, no European country (except
Austria) has developed and implemented a program for
routine vaccination in boys.
Clinical effectiveness vs economic effectiveness
An overview of the results of many economic studies
shows that vaccination against HPV produces immediate
benefits from epidemiological points of view and in
terms of avoided costs for country-specific National
Health Systems (NHSs) [79-82]. Although estimates vary
depending on the assumptions made, the cost-
effectiveness of vaccination against HPV has been con-
firmed by a large body of modeling studies, which have
been designed to evaluate different vaccination strategies
[83,84]. In general, these studies compared a single
cohort of women who underwent vaccination, plus
optional catch-up cohorts, with women who underwent
screening alone; the cohorts varied in age of immu-
nization among studies. Studies evaluated the cost-
effectiveness of vaccinating women of a particular age
(e.g. 35 years) who had been participating in a specific
screening strategy (e.g. biennial cytology) [85]. Two
studies evaluated the implementation and economic
consequences of a multi-cohort vaccination strategy
[86,87]. At present, to be considered efficient from an
economic point of view, health intervention should have
an ICER (Incremental Cost Effectiveness Ratio) per
QALY (Quality Adjusted Life Year) gained of less than
£ 20,000 to £ 30,000 [88,89] (approximately € 30,000 to
€ 45,000). It should be noted that the threshold of
£ 30.000 as defined by the National Institute for Health
and Clinical Excellence (NICE) is not transferable to the
specific policies on vaccines. The Canadian Agency for
Drugs and Technologies in Health evaluated the cost-
effectiveness of HPV vaccination in women and calcu-
lated a cost per QALY gained amounting to € 14,224 for
the HPV4 vaccine and € 21,540 for the HPV2 vaccine
[89]. Another study calculated QALY gained for HPV4
vaccines in Italy of € 9,569 [84]. In a recent study [87],
results from a multi-cohort (12, 15, 16, and 25 years old)
vaccination strategy of women confirmed the cost-
effectiveness of HPV vaccination.
Several economic evaluations have assessed various
HPV vaccine scenarios for men and women, on a cost-
effectiveness basis in terms of QALY gained [79-81].
Even so, most cost-effectiveness studies of male vaccin-
ation tend to be centered on exclusively reducing cer-
vical cancer in women and lack further important
economic considerations – only lately have some studies
started to take into account other vaccine benefits.
The published mathematical models using both men
and women are based on assumptions that are not fully
evidence-based. There are few studies that include malesand those that are available also do not include all HPV-
related diseases in both sexes and the coverage and com-
pliance rates. Increasing coverage rates in females is a real
challenge in most countries and is unlikely to be realized,
unless a considerable budget effort is made by health
authorities (public health campaigns, etc). The CDC
recommendation (in November 2011) that young boys, as
well as girls, should get immunized against HPV was
based on the statement that male inclusion is cost-
effective when coverage rates in females are low, such as is
the case in the United States. In Australia, where the HPV
vaccine coverage in female is high (> 80%), the decision to
include routine vaccination of boys 12/13 years of age
(recommended by the Pharmaceutical Benefits Advisory
Committee (PBAC) [90]) was supported by showing that
male inclusion could be cost-effective in Australia [91].
Following the Australian example, in January 2012 the
National Advisory Committee on Immunization (NACI)
in Canada recommended extension of the HPV4 vaccine
to males between 9 and 36 years of age and routine
vaccination of 12-year-old boys [78]. When more non-
cervical diseases are included, cost per QALY gained
decreased significantly. Moreover, not incorporating the
reduction of number of non-cervical cancer cases in both
sexes leads to a substantial underestimation of the cost
per QALY gained of extending the vaccination to males.
Elbasha et al. [92] presented all epidemiological outcomes
and the number of cases avoided by vaccinating males in
addition to females. The most oncogenic HPV type caus-
ing the greatest burden may be the most difficult to elim-
inate through vaccination of girls only; more substantial
incremental benefits are expected by adding boys to vac-
cination programs when the HPV vaccine coverage is <
50% among young girls [93]. The cost/effectiveness of the
impact on the overall population of including routine vac-
cine to MSM is still to be better defined. Boys and girls
will mostly benefit from HPV vaccination if vaccinated
routinely before becoming sexually active. In addition to
protecting heterosexual males and their female partners,
routine vaccination of boys at a young age is also the best
way to reach MSM at an age when they could most bene-
fit [74]. Furthermore, in the early stages of sexual life for a
significant number of MSM, heterosexual activity is not
uncommon thus contributing to the transmission of the
virus [94]. Burden of disease in men seems to be quite sig-
nificant, because genital warts alone have an important
economic and psychological burden. Models taking into
consideration several factors such as other HPV-related
diseases seem to prove that male vaccination is expected
to be cost effective.
Introduction to male vaccination
One of the main goals of vaccination programs is to stop
the transmission of an infective agent. In the case of
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goal. Moreover, why should vaccination programs target
only one single disease such as cervical cancer, when
vaccine benefits have also been proven to be high against
other HPV-related diseases? Vaccinating boys is expec-
ted to facilitate the eradication of the cervical cancer,
reduce the transmission of the virus, increase herd
immunity, and contribute to the prevention of HPV-
associated diseases in both genders. In fact more incre-
mental benefits are expected by adding the boys in the
vaccine program [93].
Neither the EMA nor the European Centre for Disease
Prevention and Control (ECDC) guidelines [95] formally
recommend vaccinating programs in boys or men.
Among the scientific endorsements of an inclusion of
males into vaccination programs for females, two differ-
ent multidisciplinary panels of experts were convened
between 2010 and 2012 in Italy. The Italian Society of
Andrology, the Italian Society of Urologists, and the Ital-
ian Society of Andrology and Sexual Medicine created a
panel of experts which developed a consensus statement
arguing that the vaccine should be offered to males [96].
The second panel developed a commitment platform
among scientists that is the basis of this paper. Italy is
now also offering the vaccine on demand to males with
a strategy of co-payment although informational and
promotional campaigns have not been finalized yet.
Men play a key role in the paradigm of HPV infection:
both as patients and as part of the mechanisms of trans-
mission. As mentioned before, data show men are af-
fected almost as frequently as women. Moreover no
screening procedures for HPV prevention are currently
ongoing in men, who do not receive routine medical
testing by any medical specialist; in general the attitude
in men towards prevention is low. They also do not
benefit from government prevention strategies. It is well
known that flat penile lesions play an important role in
the transmission of high risk HPVs. In women the anal
mucosa is a reservoir of HPV, which can be a source of
re-infection for the cervix [97]. However, as observed in
the mentioned study, there was not a significant associ-
ation between the anal sex practice and the prevalence
of anal cytological abnormalities. Including men in HPV
vaccination programs increases its ranking on the list of
urgent decisions to be taken by policy makers [98-101].
Information on HPV-related diseases is low or lacking in
men; however, from studies focused on the acceptance
by parents of vaccination of boys, it appears they would
be willing to vaccinate their male children [102-104] and
inclusion of men in the vaccine program will also in-
crease coverage in women [105-107]. Discussion regard-
ing the introduction of male vaccination is ongoing.
Several key points could help in the extension of HPV
vaccination programs to men such as: female-onlyvaccination will not protect all men; HPV-related head
and neck cancer burden is carried mainly by men; it is
the fastest way to achieve female protection by means of
herd-immunity; vaccinating males is a more gender-
equitable public health policy; men seem to accept vac-
cination as do parents of boys; vaccine seems to elicit
the same if not a higher degree of immunogenicity in
boys than in girls; genital warts and HPV-related cancers
in men represent costly and emotionally burdensome
and preventable conditions; lessons from the past with
other vaccines show that single-gender-based vaccin-
ation policies are less effective.
“…there is a good chance of drastically reducing
cervical cancer by vaccination…. HPV-16 and -18
could probably be eliminated if we have a global
program. You could theoretically achieve this by
vaccinating only girls, but you would need very high
coverage. I’m a strong advocate for vaccinating boys as
well: we’ll reach the goal much faster by vaccinating
both sexes. The disadvantage is that the cost is very
high…” [108].
The HPV4 vaccine has proved to be effective and safe
in men, but whether this is enough to recommend inclu-
sion of males in NHS prevention strategies is still being
debated. Several factors such as vaccine efficacy, herd
immunity, vaccine coverage rates in females, burden of
disease in men, and cost-benefit ratios need to be further
evaluated when including men into the formula.Summary
Achievements, pending questions, next steps
Vaccines are among the few medical interventions cap-
able of achieving almost complete eradication of a dis-
ease. Today’s available epidemiological data show that
HPV do not affect men and women differently and that
men carry a considerable burden of the disease, enough
to justify being included in national recommendations
for immunization programs against HPV-associated le-
sions. Both the EMA and the FDA have approved HPV4
vaccine indication in males 9-26 years of age. Some
national public health authority boards, such as in the
USA, Canada, and Australia, already recommend men
being included in their anti-HPV national routine immu-
nization programs. So far, except for Austria, it is not yet
recommended in Europe.
Taking advantage of the increasing opportunity to re-
duce HPV infection and transmission among sex partners,
and of the increasing evidence on the effectiveness/effi-
cacy of the HPV vaccines in preventing the development
of HPV-related diseases, will decrease the burden of dis-
ease and increase the quality of life in the communities.
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more incremental benefits globally to the currently un-
solved and severe problem of HPV infection [93,109].
Those achievements pose questions for decision-makers
as to their duty to overcome any barrier that impedes the
achievement of health protection for both women and
men against HPV infection. The issue of social equity in
healthcare for both men and women is also one that must
be addressed.
Future evaluation by the decision-makers in various
countries of the results obtained by the next generation of
intervention programs will focus on the critical issues that
still exist: a) previous experience in gender-restricted vac-
cination programmes has demonstrated a substantially
lower effectiveness than universal vaccination;b) limiting
vaccination to women might increase the psychological
burden on women by confirming a perceived inequality of
the sexes; c) even if all women were immunized, the HPV
chain of transmission would still be maintained through
MSM; d) the cost-effectiveness of including boys in HPV
vaccination programs should be re-assessed in view of the
increased reduction, due to universal vaccination, of the
economic burden of HPV related diseases in men and
women [110].
Therefore steps must be taken by recommendation bod-
ies and stakeholders to achieve the expected results of
universal vaccination - the eradication of HPV infection.
The goal to eradicate sexually transmitted carcinogenic vi-
ruses can be accomplished jointly by women and men
within a few decades [111].
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